Miklós Egyed

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 366 citations

Hematological Malignancy, Relapsed Multiple Myeloma, Medicine +11

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown et al. · The Lancet Oncology · 2017 · 247 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +11

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Hajnalka Andrikovics, Tünde Krähling, Katalin Balassa et al. · Haematologica · 2014 · 98 citations · Full text

Somatic Insertions/deletions, Hematological Malignancy, Calreticulin Mutations +15

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta et al. · Blood Advances · 2023 · 44 citations · Full text

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2023 · 33 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +8